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ABSTRACT
Background
Observational studies suggest that male circumcision may provide protection against HIV-1
infection. A randomized, controlled intervention trial was conducted in a general population of
South Africa to test this hypothesis.
Methods and Findings
A total of 3,274 uncircumcised men, aged 18–24 y, were randomized to a control or an
intervention group with follow-up visits at months 3, 12, and 21. Male circumcision was offered
to the intervention group immediately after randomization and to the control group at the end
of the follow-up. The grouped censored data were analyzed in intention-to-treat, univariate
and multivariate, analyses, using piecewise exponential, proportional hazards models. Rate
ratios (RR) of HIV incidence were determined with 95% CI. Protection against HIV infection was
calculated as 1 RR. The trial was stopped at the interim analysis, and the mean (interquartile
range) follow-up was 18.1 mo (13.0–21.0) when the data were analyzed. There were 20 HIV
infections (incidence rate¼0.85 per 100 person-years) in the intervention group and 49 (2.1 per
100 person-years) in the control group, corresponding to an RR of 0.40 (95% CI: 0.24%–0.68%; p
, 0.001). This RR corresponds to a protection of 60% (95% CI: 32%–76%). When controlling for
behavioural factors, including sexual behaviour that increased slightly in the intervention
group, condom use, and health-seeking behaviour, the protection was of 61% (95% CI: 34%–
77%).
Conclusion
Male circumcision provides a degree of protection against acquiring HIV infection, equivalent
to what a vaccine of high efficacy would have achieved. Male circumcision may provide an
important way of reducing the spread of HIV infection in sub-Saharan Africa. (Preliminary and
partial results were presented at the International AIDS Society 2005 Conference, on 26 July
2005, in Rio de Janeiro, Brazil.)
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Male circumcision (MC) is associated with various cultural
factors, including religious sacriﬁce, rites of passage into
adulthood, and the promotion of hygiene. The earliest
documentary evidence for circumcision is from Egypt. Tomb
artwork from the Sixth Dynasty (2345–2181 B.C.) shows
circumcised men, and one relief from this period shows the
rite being performed on a standing adult male. Genesis
(17:11) places the origin of the rite among the Jews in the age
of Abraham, who lived around 2000 B.C.
Presently, MC practices in Africa are varied. Whereas men
in Muslim countries are circumcised, as in North Africa or a
large part of West Africa, in other societies the prevalence of
MC depends on other cultural factors, such as changes that
occurred under colonization. In countries such as Cameroon
and the Democratic Republic of Congo, which are predom-
inately non-Muslim, most men are circumcised [1–3]. In
Kenya, where only a minority of men are Muslims, men in all
tribes except the Luo practice MC [4].
The ﬁrst paper suggesting a protective effect of MC against
HIV infection was published in 1986 [5]. Since then, many
observational studies have been published, some of which
have observed that most men living in East and southern
Africa, the regions with the highest prevalence of HIV, are
not circumcised [1–3]. A majority of these observational
studies are cross-sectional, and a minority are prospective [6–
11]. A systematic review and meta-analysis found that in sub-
Saharan Africa MC is associated with a signiﬁcantly reduced
risk of HIV infection among men, with an adjusted relative
risk of 0.42 (95% CI: 0.34%–0.54%) [12].
All of these studies were based on observational data, and,
in the absence of experimental studies, a causal relationship
between MC and protection against HIV infection could not
be determined [13]. Direct experimental evidence is needed
to establish this relationship and, should a protective effect of
MC be proven, to convince public health policy makers of the
role of MC in reducing the spread of HIV [7,13,14].
The primary objective of this study was to determine the
impact of MC on the acquisition of HIV by young men
through a randomized, controlled, blindly evaluated inter-
vention trial. The secondary objective was to assess the role of
behavioural factors known to be associated with HIV
serostatus in explaining the possible impact. This study was
conducted in the Gauteng province of South Africa, where
HIV prevalence among pregnant women was estimated to be
29.6% in 2003 [15]. According to an earlier study in the
research site area, 59% (95% CI: 55%–63%) of uncircumcised
men said that they would be circumcised if it reduced their
chance of acquiring HIV and STDs [16].
Methods
General Presentation
A randomized, controlled, blindly evaluated intervention
trial was carried out in Orange Farm and surrounding areas, a
semi-urban region close to the city of Johannesburg. The
recruitment of participants took place in the general
population from July 2002 to February 2004. Information
about the trial was disseminated in the community through
meetings during the recruitment period. Precise oral and
written information was delivered at the investigation centre
to potential participants during a pre-screen visit. Partic-
ipants were then informed that the impact of MC on the
acquisition of sexually transmitted infections (STIs), includ-
ing HIV, is not known. A minimum of 3 d after the pre-screen
visit, potential participants were screened for eligibility.
Potential participants with genital ulcerations were tempo-
rarily excluded until successful treatment. The inclusion and
exclusion criteria are listed in Table 1. The participants
received a total of 300 South African Rand as compensation
(1 South African Rand ; 0.12 Euro). The protocol, the
consent form, and the participant information sheet are
provided as Text S1–S3.
Randomization
At the end of the screen visit, following screening and
written consent, participants were divided into two groups,
using sealed envelopes. Participants requested to participate
actively in the random assignment. Consequently, each
participant was invited by the manager of the centre to
choose an envelope containing the group name from a basket
of ten envelopes. After each randomization, a new envelope
was added to the basket. This added envelope was taken
sequentially from a set of envelopes pre-prepared in such a
way that each set of envelopes contained ﬁve for the
‘‘Control’’ and ﬁve for the ‘‘Intervention’’ arm. Participants
of the intervention group were offered to be circumcised
within a week. Participants of the control group were asked to
wait until the end of the trial before being offered to be
circumcised.
Follow-Up and Data Collection
After the screen visit, which took place at month 1 (M1), the
three follow-up visits took place at the end of M3, M12, and
M21. The M3 visit was designed to study the possible impact
of surgery on HIV acquisition as a result of sexual activity
during the healing phase following circumcision or contam-
ination during surgery. These three follow-up visits deﬁned
three sequential periods, M1–M3, M4–M12, and M13–M21,
with expected durations of 3, 9, and 9 mo, respectively. The
duration of these periods was measured in days from the
dates of the visits, the day after the end of a period being the
beginning of the next period.
A participant lost to follow-up was deﬁned as a participant
Table 1. Inclusion and Exclusion Criteria
Type Criterion
Inclusion criteria To be a male between the age of 18 and 24
To wish to be circumcised
To reside in the Orange Farm area or surrounding areas
To be able to understand the nature of the trial
To agree to be randomized to either of the two groups
(the intervention group and the control group)
To agree to come to three follow-up visits
To agree to answer general health questions and questions
related to sexual activity
To agree to have genital examinations
To agree to give blood samples tested for HIV and syphilis
Exclusion criteria To be circumcised
To have had any contraindication to MC
DOI: 10.1371/journal.pmed.0020298.t001
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Male Circumcision Trialwho had not completed a planned visit in the 2 mo following
the planned date of this visit and who did not complete any
further visit. A missing visit was deﬁned as a visit not
completed prior to a completed visit.
At each of the four visits, each participant was invited to
answer a face-to-face questionnaire, to provide a blood
sample, and to have a genital examination and an individual
counselling session. The questionnaire allowed for collection
of data on background characteristics and reported sexual
behaviour. The last section of the questionnaire allowed for
the description of all sexual partnerships over the previous 3
mo for the M3 visit and over the previous 12 mo for all other
visits. This section allowed each participant to describe the
number of sexual contacts, the date of ﬁrst and last sexual
contact, the frequency of condom use (never, sometimes,
always), and the type of partnership (spousal or non-spousal),
a spousal partner being deﬁned as a sexual partner with
whom the respondent is married or living as married.
Characteristics of sexual behaviour during the 9-mo periods
M4–M12 and M13–M21 were determined from this section,
using the dates of ﬁrst and last sexual contact of each sexual
partner. The genital examination was performed by a trained
nurse who recorded the circumcision status and took a blood
sample from each participant. Blood samples were tested for
syphilis and HIV-1.
The counselling session (15–20 min) was delivered by a
certiﬁed counsellor and focused on information about STIs
in general and HIV in particular and on how to prevent the
risk of infection. During this session, participants were
encouraged to attend voluntary counselling and testing in a
public clinic located 200 m away from the investigation
centre or in a voluntary counselling and testing (VCT) centre
funded by the project and located in the same building as the
investigation centre. Condoms were provided in the waiting
room of the investigation centre and were also provided by
the counsellor. Participants who had symptoms of STIs, as
assessed by the nurse during the genital examination, or who
tested positive for syphilis were treated at the local clinic or
by doctors working for the project. A speciﬁc programme for
prevention of opportunistic infections and delivery of
antiretroviral treatment, if required, was put in place at the
VCT centre to assist participants who attended VCT and who
tested positive for HIV. The arrangement will remain in place
until the public sector programme becomes operational in
the area.
The standard of care in South Africa at the beginning of
the trial in July 2002 included VCT but not access to
antiretroviral therapy. With the formal introduction of access
to antiretroviral therapy in 2004, there were increased efforts
to encourage participants to attend VCT and referrals to
appropriate facilities were instituted. In this context, it was
decided to include participants independent of VCT attend-
ance. Consideration for making HIV testing compulsory for
participation in the trial or recruiting only those who tested
HIV-negative would certainly lead to stigmatization, and the
investigators considered that the whole concept of VCT was
that it should be voluntary. They considered it unethical to
inform participants of their HIV status without their
permission, even if they thought that participants should be
aware of their HIV status. They also considered it unethical to
deter from participating in the study potentially at-risk men
who did not want to know their HIV status. Indeed, HIV-
positive participants would beneﬁt from the trial: (a) by
receiving counselling at each visit, (b) by undergoing clinical
examination and syphilis testing, and (c) by having a
medicalized circumcision that could possibly protect them
or their sexual partners against other STIs or even against re-
infection by HIV.
Male Circumcision
The median (interquartile range [IQR]) duration between
randomization and MC was one day (0–2). The circumcisions
were performed by three local general practitioners in their
surgical ofﬁces. The general practitioners were experienced
in MC practices. The cost of each circumcision was 300 South
African Rand and was paid for by the project. The procedure
was standardized and used the forceps-guided method, as is
widely practiced in South Africa, and was reviewed by the
Department of Urology, University of the Witwatersrand
Medical School, South Africa.
Quality of the Data, Blinding, Confidentiality, and Data
Management
To ensure conﬁdentiality, participants’ ﬁles were kept in a
locked room at the centre and each participant received a
number that was used to identify all documents related to
that person. To ensure blinding of study personnel, the
randomization group information was not available to the
personnel in charge of counselling or collecting information
in the centre during the participants’ visits.
Questionnaires were checked at the end of each interview.
Participants failing to turn up for any follow-up visit were
visited at home by trial staff, who encouraged them to come
for the follow-up visits or ascertained the reasons for
dropping out.
Laboratory results were stored in a database that was
independent of the one used to store the information related
to each participant. During the study, no HIV results were
available to the investigation centre or to the investigators,
apart from the statistician in charge of the interim analysis.
Laboratory results and data collected from questionnaires
were entered twice in a database (Microsoft Access, Redmond,
Washington, United States) by different people. The two
entries were compared, and discrepancies were corrected.
The data were then re-checked for inconsistencies using the
source documents. After the data had been cleaned, they were
imported into the statistical package SPSS for Windows
version 8 (SPSS, Chicago, Illinois, United States) and R
(version 2.0.1) for analysis [17].
Laboratory Procedures
Following the interview, a trained nurse collected whole
blood samples in the investigation centre. One EDTA blood
tube of 10 ml of venous blood was taken and immediately
centrifuged at 400 g for 10 min, and ﬁve aliquots of plasma
were frozen at 20 8C. The samples were identiﬁed only by the
participant number and transported each week to the
laboratory, where they were stored at  70 8C and tested.
An ELISA screen (Genscreen HIV1/2 version 2, Bio-Rad,
France) and two ELISA conﬁrmatory tests (Wellcozyme HIV
recombinant, Abbott Murex, Dartford, United Kingdom, and
Vironostika HIV Uni-Formm II plus O, bioMe ´rieux, Boxtel,
Netherlands) were used to test plasma for HIV-1 infection.
Samples that were positive on all three ELISAs were regarded
as ‘‘positive’’ and all others as ‘‘negative’’ [18].
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The research protocol was reviewed and approved by the
University of Witwatersrand Human Research Ethics Com-
mittee (Medical) on 22 February 2002 (protocol study no.
M020104). The trial was also approved by the Scientiﬁc
Commission of the French National Agency for AIDS
Research (ANRS; protocol study no. 1265; 2002, decision
No. 50) and obtained authorization from the City of
Johannesburg, Region 11, on 25 February 2002. A Data and
Safety Monitoring Board was responsible for analyzing
adverse events and for deciding on the results of the interim
analysis.
Adverse Events
Adverse events (AEs) were documented and analyzed for all
participants, including those who were HIV-positive at
randomization. These AEs related to surgery, and that
occurred in the ﬁrst month post-surgery, were reported by
the practitioners using a speciﬁc form. In addition, at each
visit to the centre the nurse completed a questionnaire after
the genital examination to record adverse events. During
home visits for missing participants, any deaths were
recorded.
Sample Size and Interim Analysis
The total sample size was initially calculated to be 2,580
HIV-negative participants in order to obtain a power of 80%
to detect a 50% reduction in the proportion of HIV infection
between the groups at a 5% signiﬁcance level, assuming an
HIV incidence of 2.2 per 100 person-years (py) in the control
group. This number, calculated using Fisher’s exact test, was
increased to 3,035 to account for 15% of participants lost to
follow-up. An interim analysis was planned for when all the
M12 visits had been completed, and this was conducted blind
with the database obtained on 29 November 2004. At the time
of the interim analysis, the total follow-up included an
estimated 63% of the total number of py that would have
been collected at the end of the study, leading to a threshold
value of 0.0095, as determined by the Lan-DeMets alpha-
spending function method [19].
Statistical Analysis
While participants with a HIV-positive test at M1 were
followed in the same way as the other participants, they were
excluded from the statistical analysis. HIV status was
considered as censored data with time being continuous,
observed in a grouped form (at the end of each period), with
non-uniform duration of periods. These data were modelled
using a piecewise exponential, proportional hazards model in
which the baseline hazard is constant in each period. This
theoretical model allows the precise duration between each
visit and time-dependent covariate to be taken into account.
It was implemented by running a Poisson log-linear model on
a dataset composed of lines corresponding to the periods
M1–M3, M4–M12, and M13–M21, in which the participant
stayed HIV-negative or became HIV-positive [20–22]. Con-
sequently, in this dataset, each individual was represented by
a maximum of three lines. This type of model gives an
incidence rate and incidence rate ratio (RR) of HIV infection
among men of the intervention group in comparison with
men of the control group. The protection against HIV
infection was calculated as 1   RR.
At the interim analysis, the RR was 0.37 in the intervention
group, as compared with the control group, with a p value of
0.00073, below the threshold value. The Data and Safety
Monitoring Board advised the investigators to interrupt the
trial and offer circumcision to the control group, who were
then asked to come to the investigation centre, where MC was
advised and proposed. The database corresponding to
planned visits up to 30 April 2005 was then analyzed, and
the results are presented in this paper. Because the study was
interrupted, some participants did not have a full follow-up
on that date, and their visits that were not yet completed are
described as ‘‘planned’’ in this article.
Adjusted rates and RRs were obtained by taking into
account covariates that were calculated for each period when
they were time-dependent. Three nested models were
developed. The model-1 included the period number, which
was included as categorical variables, with the logarithm of
the duration of exposure in each period in days as an offset.
In the model-2, the calendar period of recruiting and
background characteristics of the participants were added.
In the model-3, behavioural time-dependent covariates,
characterizing the behaviour of participants during each
period, were also added.
The background characteristics of the participants consid-
ered were age (less than or equal to 21 y, more than 21 y),
religion (Catholic or Protestant, African traditional, other),
ethnic group (Zulu, Sotho, other), and alcohol consumption
in the past month. The ﬁve reported sexual behaviour
covariates considered were, for each period of follow-up,
being at-risk behaviour (deﬁned as having at least one sexual
contact unprotected by condom), having a spousal partner,
the number of non-spousal sexual partners, the number of
sexual contacts, having at least one relationship with only one
sexual contact. In addition, health-seeking behaviour was
characterized by at least one visit to a clinic for a genital
problem during the 12-mo period prior to a visit to the
centre.
Additional analyses were also performed. (a) The impact of
the intervention was assessed among those having completed
their M21 visit. (b) The impact of the intervention on
participants who were 1 mo or more late to at least one
follow-up visit or missed one follow-up visit was compared
with the impact of the intervention on other participants by
testing the corresponding interaction term between this
factor and the randomization group. (c) To analyze the
impact of the 6-wk period of abstinence, the analysis was
repeated with the duration of the period M1–M3 reduced by
42 d in the intervention group. Forty-two days was the
median (IQR ¼ 28–56) interval between MC and ﬁrst sexual
contact reported by sexually experienced participants of the
intervention group. (d) The effects of MC across the ethnic
groups were studied by assessing this impact among the two
major ethnic groups of this study (Zulus and Sothos) and by
testing the corresponding interaction term. (e) Finally, while
all analyses were performed in intention-to-treat, a per-
protocol analysis was performed using the circumcision
status observed at each visit.
Six comparisons of the behavioural factors for each of the
periods M4–M12 and M13–M21 were performed. Independ-
ence of behavioural categorical data between the random-
ization groups was tested using Fisher’s exact test, and the
Kruskal-Wallis test was used for quantitative behavioural
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ent, and to keep the overall risk of type I error equal to 0.05,
the level of signiﬁcance was set as 1.00   0.95
1/6 ¼ 0.0085.
Results
Table 2 gives the baseline characteristics for the HIV-
negative participants. The median age (IQR) was 21.0 y (19.6–
22.5). Most of the participants had completed the primary
level of education. Very few were married or living as married,
and about half were at-risk behaviour. Figure 1 shows the trial
ﬂowchart. A total of 3,274 men participated in the trial. There
were 146 (prevalence 4.5%) HIV-positive participants at
randomization. The difference in size between the interven-
tion and control group was 34 (1,620 versus 1,654).
Among the 3,128 HIV-negative participants at random-
ization, the visits at M3, M12, and M21 took place at (median;
IQR) 3.0 (3.0–3.2), 12.0 (11.9–12.1), and 20.9 mo (20.9–21.2)
after randomization, respectively. The mean (IQR) follow-up
was 18.1 mo (13.0–21.0).
The fraction of participants lost to follow-up was 8.0 %
(251/3128), with 6.5% (100/1546) in the intervention group
and 9.5% (151/1582) in the control groups (p¼0.0016, Fisher’s
exact test). Among the participants lost to follow-up at the
visit M12 or M21, none (0/124) were HIV-positive at their
previous completed visit.
During the study, 20 and 49 participants acquired HIV
infection in the intervention and control groups, respectively,
corresponding to incidence rates (95% CI) of 0.85 per 100 py
(0.55–1.32) and 2.1 per 100 py (1.6–2.8) in the intervention
and control groups, respectively. Using model-1, the RR of
HIV infection for the intervention group in comparison with
the control group was 0.40 (0.24–0.68), p ¼ 0.00059 (Table 3).
This RR corresponds to a protection of 60% (32–76) against
HIV infection. This result is equivalent to saying that during
the period M1–M21 the intervention prevented six out of ten
potential infections.
When considering only those participants who completed
their M21 visit, the RR was 0.38 (0.22–0.67), p , 0.001. In
comparison with the others, those who were 1 mo or more late
to at least one follow-up visit or missed one follow-up visit
(1178/3128; 37.7%) had the same risk of HIV infection (RR ¼
1.06; 0.65–1.73; p¼0.82) and were not differently protected by
MC (p¼0.69). When reducing the M1–M3 period by 42 d in the
intervention group, the RR was RR ¼ 0.43 (0.26–0.73), p ¼
0.0016, a value close to the RR obtained in the intention-to-
treat analysis. This indicates that the 6-wk period of
abstinence plays a minor role in explaining the effect of the
intervention during the period M1–M21. Among the two
major ethnic groups of the participants, Zulus (n¼1,109) and
Sothos (n ¼ 1,506), the RR was 0.60 (0.25–1.41), p ¼ 0.24, and
0.42 (0.20–0.88), p ¼ 0.022, respectively. These two RRs were
not signiﬁcantly different (p¼0.55). The per-protocol analysis
gave RR¼0.24 (0.14–0.44), p , 0.001, a value lower to the RR
obtained in the intention-to-treat analysis. The difference of
the results given by the two analyses is at least partly explained
by the cross-overs. In the intervention group, 6.5% (93/1432)
were not circumcised at M3, and in the control group, 10.3%
(114/1105) were circumcised at M21 (Figure 1).
For the periods M1–M3, M4–M12, and M13–M21, the
number of HIV infections was two, seven, and 11 in the
Table 2. Baseline Characteristics of HIV-Negative Men Enrolled in the Trial
Background Characteristics Control Intervention
n ¼ 1,582 n ¼ 1,546
Age Less than or equal to 21 y 52.4% 48.6%
More than 21 y 47.6% 51.4%
Primary level of education completed 98.4% 98.3%
Religion African traditional 47.0% 51.6%
Protestant or Catholic 11.1% 11.9%
Other religion 41.8% 36.5%
Ethnic group Sotho 47.3% 49.0%
Zulu 38.1% 32.8%
Other 14.6% 18.2%
Drank alcohol in the past month 41.9% 42.2%
Reported sexual behaviour
Have had first sexual experience 90.5% 91.8%
Median (IQR) age at first sex (years)
a 16.6 (15.2–18.4) 16.8 (15.4–18.5)
Median (IQR) number of lifetime sex partners
b 4 (2–7) 4 (3–7)
Used a condom at first sex
b 13.4% 15.2%
Ever used a condom
b 81.2% 82.3%
At-risk behaviour
c,d 46.7% 46.8%
Married or living as married
d 1.8% 1.8%
Mean (IQR) number of non-spousal partners
e 1.4 (0–2) 1.4 (0–2)
At least one sexual partnership with only one sexual contact
e 29.8% 30.7%
Mean (IQR) number of sexual contacts
e 8.0 (0–8) 8.7 (1–8)
Attended a clinic for a health problem related to the genital area
e 10.0% 9.6%
a Calculated using censored data analysis
b Among those having had first sexual experience
c Defined as having at least one sexual contact not protected by condom
d At some time during the past 12 mo before randomization
e During the past 12 mo before randomization
IQR, interquartile range
DOI: 10.1371/journal.pmed.0020298.t002
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Characteristic Period
a
M1–M3 M4–M12 M13–M21 M1–M21 (total)
Number of HIV infections 11 22 36 69
Follow-up (py) 881 2,159 1,652 4,693
Incidence rates percent py (95% CI)
b 1.25 (0.69–2.26) 1.02 (0.67–1.55) 2.20 (1.59–3.05) 1.48 (1.17–1.87)
Incidence RRs (95% CI) of intervention versus control
b 0.23 (0.05–1.04)
p ¼ 0.057
0.46 (0.19–1.13)
p ¼ 0.091
0.43 (0.21–0.87)
p ¼ 0.019
0.40 (0.24–0.68)
p ¼ 0.00059
a The follow-up periods are from M1–M3, M4–M12, and M13–M21.
b Obtained using a piecewise exponential, proportional hazards model, which was implemented with a Poisson log-linear model. Duration of exposure was the duration of each period for those staying HIV-negative and the duration of half
the period for those becoming HIV-positive (model-1; see text).
DOI: 10.1371/journal.pmed.0020298.t003
Figure 1. Trial Profile
This figure describes the state of the trial corresponding to planned visits up to 30 April 2005. HIV-positive and HIV-negative participants were
randomized. All were followed, but only participants HIV-negative at randomization were analyzed and are represented in the three follow-up visits of
the figure. After randomization, the participants could attend the 3-mo visit, miss it, or be excluded from follow-up (death or loss to follow-up). The non-
excluded participants who attended the 3-mo visit could then attend the 12-mo visit, miss it, or be excluded (death or loss to follow-up). The non-
excluded participants of the 12-mo visit could then attend the 21-mo visit, be excluded (death or loss to follow-up) or were planning to attend the 21-
mo visit but had not yet done so, because of the interruption of the trial.
*, did not come for the scheduled visit (refused, withdrew, moved away or died); **, no blood sample
DOI: 10.1371/journal.pmed.0020298.g001
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Male Circumcision Trialintervention group and nine, 15, and 25 in the control group.
The RR for each of these periods is given in Table 3. In the
period M1–M3, there was an RR of 0.23 close to the
signiﬁcance level, which was slightly higher when taking into
account the 42 d of abstinence (RR¼0.37; 0.08–1.72; p¼0.21).
Using model-2, an RR was found similar to that obtained
with model-1: 0.38 (0.23–0.65), p , 0.001. This result is
attributable to the randomization process, which distributed
the characteristics equally between the intervention and
control groups.
Of the ﬁve reported sexual behavioural factors, all were
higher in the intervention group than in the control group
during the period M4–M12, and four out of ﬁve were higher
during the period M13–M21. Only the mean number of
sexual contacts showed statistically signiﬁcant differences
during the period M4–M12 (5.9 versus 5.0, p , 0.001) and
during the period M13–M21 (7.5 versus 6.4, p ¼ 0.0015). The
proportion of participants attending a clinic for a genital
problem in the 12 mo prior to M12 was lower in the
intervention group than in the control group (4.7% versus
7.2%, p ¼ 0.0067).
Using model-3, the RR, adjusted on behavioural character-
istics, reported by participants during the follow-up is similar
to the RR obtained with model-1 (Table 4). This last result
indicates that the protective effect of the intervention is not
attributable to the change of reported behaviour associated
Table 4. Multivariate RRs of HIV Incidence
Categories of
Factors
Factors Values of Factors HIV
Cases
Follow-Up
(py)
HIV Incidence
Rates (95% CI;
per 100 py)
a
Incidence RRs
(95% CI) of
Intervention versus
Control (95% CI)
a,b
Randomization group Intervention 20 2,354 0.85 (0.55–1.32) 0.39 (0.23–0.66)
p ¼ 0.00049
Control 49 2,339 2.11 (1.60–2.80) 1
Recruitment period After 30 December 2002 41 3,251 1.27 (0.93–1.72) 0.64 (0.39–1.06)
p ¼ 0.081
At or before 30 December 2002 28 1,442 1.96 (1.35–2.84) 1
Individual
characteristics
Age group More than 21 y 46 2,284 2.03 (1.52–2.71) 1.99 (1.19–3.34)
p ¼ 0.0086
Less than or equal to 21 y 23 2,408 0.96 (0.64–1.44) 1
Religion Catholic or Protestant 25 1,845 1.36 (0.92–2.02) 0.49 (0.19–1.25)
p ¼ 0.14
Other 5 576 0.87 (0.36–2.09) 0.67 (0.40–1.12)
p ¼ 0.12
African traditional 39 2,271 1.73 (1.26–2.37) 1
Ethnic group Zulu 13 772 1.70 (0.98–2.92) 0.83 (0.48–1.42)
p ¼ 0.49
Other 23 1,689 1.37 (0.91–2.06) 1
Sotho 33 2,232 1.49 (1.06–2.09) 1.04 (0.55–2.00)
p ¼ 0.90
Drank alcohol in the previous month Yes 35 1,954 1.80 (1.29–2.51) 1.29 (0.80–2.09)
p ¼ 0.30
No 34 2,738 1.25 (0.89–1.75) 1
Behavioural
factors
Being at risk behaviour
c,d Yes 46 2,498 1.86 (1.39–2.48) 1.02 (0.57–1.83)
p ¼ 0.95
No 23 2,076 1.11 (0.74–1.67) 1
Married or living as married
d Yes 4 185 2.19 (0.82–5.83) 0.68 (0.23–1.99)
p ¼ 0.48
No 65 4,389 1.49 (1.17–1.90) 1
Number of non-spousal partners
e . 1 14 817 1.73 (1.02–2.91) 0.91 (0.44–1.87)
p ¼ 0.79
0–1 55 3,758 1.47 (1.13–1.92) 1
At least one sexual partnership with
only one sexual contact
d
Yes 14 1,009 1.39 (0.83–2.36) 0.98 (0.49–1.96)
p ¼ 0.96
No 55 3,555 1.55 (1.19–2.02) 1
Number of sexual contacts
e . 5 29 1,207 2.43 (1.69–3.50) 1.61 (0.90–2.88)
p ¼ 0.11
0–5 40 3,368 1.19 (0.87–1.63) 1
Attended a clinic for a health problem
related to the genitals
f
Yes 21 276 7.84 (5.11–12.02) 5.73 (3.33–9.84)
p , 0.001
No 48 4,299 1.12 (0.85–1.49) 1
a Obtained using a piecewise exponential, proportional hazards model, which was implemented with a Poisson log-linear model. Duration of exposure was the duration of each period for those staying HIV-negative and the duration of half
the period for those becoming HIV-positive.
b Adjusted for all variables indicated in the column (model-3; see text)
c See footnote c in Table 2
d At some time in the past 3-mo period before M3, and in the past 9-mo period before M12 and M21
e In the past 3-mo period before M3, and in the past 9-mo period before M12 and M21
f In the past 12 mo before each follow-up visit
DOI: 10.1371/journal.pmed.0020298.t004
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Male Circumcision Trialwith the intervention and shows that adjustment for potential
confounders has little effect on the association of MC and
HIV incidence.
Figure 2 shows the ﬁtted infection-free probability as a
function of time and of randomization. Table 5 describes the
60 (3.8%) AEs that were reported during surgery or in the
ﬁrst month following surgery among 1,568 MCs performed in
the intervention group, HIV-positive at randomization
included. The proportion of AE was higher among those
who were HIV-positive at randomization, and the difference
is close to signiﬁcance (p ¼ 0.056, Fisher’s exact test). At M3,
98.5% of those who were circumcised (HIV-positive at
randomization included), were ‘‘very satisﬁed’’ with the result
of the circumcision. Adverse events recorded at the end of
the follow-up (M21) are described in Table 6.
Home visits for late participants revealed 16 deaths among
participants (HIV-positive at randomization included), of
whom six had been circumcised, but examination of death
certiﬁcates, reports from doctors who carried out the MC,
interviews with relatives, and timing of these deaths revealed
no deaths related to MC. The mortality rate from the South
African Census 2001 data [23] in the age groups 15–19 and
20–24 for the black population of the Gauteng province was
2.4 and 3.9 per 1,000 per year. These ﬁgures lead to an
estimate of 3.5 per 1,000 per year at the mean age (21.0 y) of
our participants. In turn, this value leads to an estimated
number of deaths of 15.7 using the mean follow-up, which is
close to the number of deaths observed in our trial.
Discussion
This study provides the ﬁrst experimental evidence of the
efﬁcacy of MC in protecting men against HIV infection. It was
conducted in a general population, and it is the ﬁrst
randomized control trial testing the impact on health of
MC. The demonstration in this study of a causal association
between HIV infection and MC is consistent with protection
suggested by meta-analyses of observational studies [12] but
Table 5. Adverse Events during Surgery or in the First Month
following Surgery among Those Having Been Randomized in the
Intervention Group, as a Function of HIV Status at Random-
ization
Adverse Event HIV-Negative at
Randomization
(n ¼ 1,495 MC)
HIV-Positive at
Randomization
(n ¼ 73 MC)
Total
(n ¼
1,568 MC)
Death 0 (0%) 0 (0%) 0 (0%)
Pain 12 (22.2%) 1 (16.7%) 13 (31.7%)
Excessive bleeding 9 (16.7%) 0 (0%) 9 (15%)
Infection 2 (3.7%) 1 (16.7%) 3 (5%)
Damage to the penis 3 (5.6%) 1 (16.7%) 4 (6.7%)
Swelling or haematoma 9 (16.7%) 1 (16.7%) 10 (16.7%)
Anaesthesia-related
events
1 (1.9%) 0 (0%) 1 (1.7%)
Excessive skin removed 0 (0%) 0 (0%) 0 (0%)
Insufficient skin removed 4 (7.4%) 0 (0%) 4 (6.7%)
Delayed wound healing 1 (1.9%) 1 (16.7%) 2 (3.3%)
Problems with urinating 0 (0%) 0 (0%) 0 (0%)
Problems with
appearance
8 (14.8%) 1 (16.7%) 9 (15%)
Other cause 5 (9.3%) 0 5 (8.3%)
Total 54 (100%)
[3.6%]
6 (100%)
[8.2%]
60 (100%)
[3.8%]
Percentages of adverse events are given in parentheses, and percentages of MCs are given in brackets.
DOI: 10.1371/journal.pmed.0020298.t005
Figure 2. Infection-Free Probability As a Function of Time and of
Randomization
This figure represents the infection-free probability using a piecewise
exponential distribution with boundaries at M3, M12, and M21 obtained
with a Poisson log-linear model (see text). Each segment of exponential
has been fitted to the data in each period for each randomization group.
The 95% confidence intervals have been represented in the middle of
each period. x/y is the number of HIV infections observed in each period
(x) and the number of persons at the beginning of the period (y).
DOI: 10.1371/journal.pmed.0020298.g002
Table 6. Adverse Events at the End of the Follow-Up (M21) among Those Having Been Randomized in the Intervention Group, As a
Function of HIV Status at Randomization
Adverse Event HIV-Negative at Randomization
(n ¼ 1,131 M21 visits)
HIV-Positive at Randomization
(n ¼ 54 M21 visits)
Problem with urinating
a 3 (27.3%) 0 (0%)
Dissatisfied with the appearance of the penis
a 4 (36.4%) 0 (0%)
Mild or moderate erectile dysfunction
a 4 (36.4%) 0 (0%)
Torsion of penis
b 0 (0%) 0 (0%)
Total (%) 11 (100%) [1.0%] 0 (100%) [0%]
Percentages of adverse events are given in parentheses, and percentages of MC are given in brackets.
a Reported by participants
b Collected by a nurse
DOI: 10.1371/journal.pmed.0020298.t006
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Male Circumcision Trialwith a higher protective effect. This difference can be
explained, at least partly, by the effect of bias and confound-
ing factors associated with cross-sectional studies. High values
ranging from 0.12 to 0.29 of protective effect of MC have
been reported in prospective studies conducted in high-risk
groups [6,8–11]. Our study is also the ﬁrst experimental study
demonstrating that surgery can be used to prevent an
infectious disease. In addition, this ﬁnding is an a posteriori
proof of the use of MC to improve hygiene in the common
meaning of not being infected.
This study has some limitations. It was conducted in one
area in sub-Saharan Africa and, therefore, may not be
generalizable to other places. Nevertheless, because of the
similar route of transmission of HIV in sub-Saharan Africa
and because observational studies from various areas of sub-
Saharan Africa have shown an association between HIV status
and MC [12], the result of this trial is applicable to all of sub-
Saharan Africa with some degree of conﬁdence.
Even though some participants were lost during the follow-
up, and the loss to follow-up rate was greater than the event
rate, the impact of missing participants on the overall results
of this study is likely to be small not only because the loss to
follow-up was small for a cohort study conducted in a general
population, but also because those who were late for at least
one follow-up visit were protected by MC just as the other
participants. The reason for this loss to follow-up was a result
of participants moving from the area or being unreachable,
and not a result of HIV infection.
Because the Data and Safety Monitoring Board recom-
mended to stop the trial after the intermediate analysis, it was
not possible to follow all the participants as initially planned,
and, as a consequence, only those participants recruited at
the beginning had a full follow-up. This potential bias was
taken into account by adjusting the analysis for the recruit-
ment period; such an adjustment cannot fully account for the
confounding effect associated with partial follow-up. When
restricting the analysis to those participants who had a full
follow-up, the intervention had an effect that was similar in
size and signiﬁcance, suggesting that this potential bias had a
negligible impact.
A speciﬁc survey was implemented after the end of the
recruiting period in order to assess the satisfaction of the
results of the randomization. Of the participants, 65.3% said
they were happy. However, the results also showed that a
limited number of participants (7.5%), strongly unhappy with
their group of randomization, were allocated and recorded in
the other group. They were analyzed in their randomization
group in the intention-to-treat analysis. The ﬁndings were
conﬁrmed by the person in charge of randomization. This
factor contributed to increase the cross-over, which remained
low, and to dilute the measure of the effect of the
intervention, which remained high.
Another limitation concerns the timescale of this study.
Participants were followed up for a short period of time, and,
therefore, this study did not explore the long-term protective
effect of MC.
T h ep r o t e c t i v ee f f e c to fM Co nH I Vi n f e c t i o nw a s
unchanged when controlling for sexual behaviour, including
condom use, which was taken into account when deﬁning
those at-risk behaviour, the period of abstinence in the
intervention group following MC, and heath-seeking behav-
iour, which was considered because treatment of STIs can
have an effect on HIV acquisition [24]. This shows that these
factors play a minor role in explaining the protective effect of
MC on HIV infection. The reasons for this protective effect of
MC on HIV acquisition have to be found elsewhere, and
several direct or indirect factors may explain this [25]. Direct
factors may be keratinization of the glans when not protected
by the foreskin, short drying after sexual contact, reducing
the life expectancy of HIV on the penis after sexual contact
with an HIV-positive partner, reduction of the total surface
of the skin of the penis, and reduction of target cells, which
are numerous on the foreskin [26]. Indirect factors may be a
reduction in acquisition of other STIs, which in turn will
reduce the acquisition of HIV. Our study does not allow for
identiﬁcation of the mechanism(s) of the protective effect of
MC on HIV acquisition.
The ﬁrst and obvious consequence of this study is that MC
should be recognized as an important means to reduce the
risk of males becoming infected by HIV. As shown by our
study, MC is useful and feasible even among sexually
experienced men living in an area with high HIV prevalence.
Indeed, in our study the intervention delivered by local
general practitioners resulted in a limited and reasonable
number of adverse events and did not lead to an increase in
deaths. In addition to the protective role in men, MC will
indirectly protect women and, therefore, children from HIV
infection because if men are less susceptible to HIV
acquisition, women will be less exposed. Moreover, MC may
also be protective against male-to-female HIV transmission,
but this will require further investigation [7]. The role that
women can play in promoting MC is potentially important. If
women are aware of the protective effect of MC, this
awareness could, in turn, have an impact on the prevalence
of MC by encouraging males to become circumcised.
It was found that the protective effect of MC is high. MC
provides a degree of protection against acquiring HIV
infection equivalent to what a vaccine of high efﬁcacy would
have achieved. Consequently, the authors think that MC
should be regarded as an important public health interven-
tion for preventing the spread of HIV. MC could be
incorporated rapidly into the national plans of countries
where most males are not circumcised and where the spread
of HIV is mainly heterosexual. This is even more important at
a time when no vaccine or microbicides are currently
available and when delivering antiretroviral treatments under
WHO guidelines will have only a small impact on the spread
of HIV [27]. In addition, MC is an inexpensive means of
prevention, performed only once, and men can be circum-
cised over a wide age range, from childhood to adulthood.
The potential impact of prevention programmes based on
MC is difﬁcult to assess at population level and requires
modelling. From the results of this study and of the meta-
analysis quoted above, it can be predicted that widespread
MC could lead to a strong reduction of the spread of HIV.
The availability of a simple and ancient practice with a high
potential effect on the spread of HIV is remarkable and
should encourage decision makers to take MC into consid-
eration as policy. Because most of southern and East Africa is
concerned, the number of HIV infections that could be
avoided by the widespread implementation of MC is high.
There are potential risks in promoting MC as way of
reducing the risk of HIV infection. MC can be performed
under poor hygienic conditions, leading to not only infection,
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Male Circumcision Trialbleeding, and permanent injury, but also HIV infection from
non-sterilized instruments, and possible death if appropriate
treatment of sequelae is not provided. In the healing period,
sexually active men are likely to be at a higher risk of HIV
infection, and this risk should not be underestimated. MC
does not provide full protection and, if perceived as full
protection, could lead to reduction of protection of men who,
for example, decrease their condom use or otherwise engage
in riskier behaviour. It was found that the intervention group
had signiﬁcantly more sexual contacts. While the protective
effect of circumcision remained despite this increased risk,
this should be a concern when considering implementation of
circumcision as a means of preventing HIV infection. Finally,
there is the danger of confusing MC with female circum-
cision, and that promotion of MC could be used by defenders
of female circumcision to defend this practice.
Acceptability studies of the use of MC as a prevention
measure against the spread of HIV have been conducted in
South Africa [16,28], Kenya [29,30], Zimbabwe [31], and
Botswana [32]. These studies, in which most of the uncircum-
cised African men expressed interest in becoming circum-
cised if performed safely and affordably, highlighted the
potential of MC as a population-level intervention to reduce
HIV spread. MC is a not a universal cultural practice, and
cultural practices can be barriers in policy considerations.
However, there are examples showing that the prevalence of
MC can be changed. For example, in South Korea 50 years
ago, almost no men were circumcised; today some 85% of
Korean men 16–29 y old are circumcised [33].
The experimental demonstration of the protective effect of
MC on the acquisition of HIV emphasizes the role of MC in
explaining the heterogeneity of HIV prevalence in sub-
Saharan Africa. From a multi-site study conducted in four
African countries, MC, together with sexual behaviour, has
been posited as an important factor in the heterogeneity of
HIV prevalence in sub-Saharan Africa [34]. This role is
conﬁrmed and reinforced by the ﬁndings of the present
study.
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Patient Summary
Background HIV/AIDS is one of the greatest threats to health worldwide.
More than 3 million people died of AIDS last year, and about 5 million
others became infected with HIV, bringing the total number of people
living with the infection to nearly 40 million. The situation is particularly
severe in Africa, which has 10% of the world’s population but two-thirds
of the world’s people with HIV. In many African tribal groups, men are
circumcised, usually in late childhood or early adolescence, and this is an
important part of their cultural identity. In other African ethnic groups,
men are not circumcised. By the late 1980s, researchers noticed that HIV
infection rates were lower in those tribes where men were circumcised.
But it was not clear whether it was circumcision itself or some other
difference in behaviour between the circumcised and uncircumcised
groups that gave some protection to the circumcised men against
getting HIV.
What Did The Researchers Do? The researchers wanted to find out
whether circumcising men could reduce their chance of becoming
infected by HIV. They offered young, sexually active, heterosexual,
uncircumcised men in Johannesburg, South Africa, the chance to have
the operation. They explained that half of those who came forward
would be circumcised right away (the ‘‘treatment group’’) and the other
half would be circumcised 21 months later (the ‘‘control group’’). Some
3,000 men joined the study. The group that each man was put into was
decided at random. The plan was that all the men would visit the
research clinic four times during this 21-month period, and that they
would be tested for HIV each time. However, after 14 months, the
number of new infections in the control group (49) was so much greater
than the number in the treatment group (20) that it was considered
unethical to continue the study. (The men in the control group were told
they could be circumcised without any further delay.)
What Do These Findings Mean? Infections were 60% fewer in the
treatment group, which seems to indicate that circumcised men are
much less likely to become infected with HIV when having sex with
infected women. In communities where HIV is common, circumcision
may prove to be a valuable tool for reducing men’s risk of getting
infected. However, as with most studies, criticisms could be made of
some aspects of the methods used, and more research is needed before
we can be sure. We must also remember that circumcised men can still
become infected, even though the risk might be lower. They should still
take other steps to prevent themselves from getting HIV.
Where Can I Get More Information Online? The United Nations health
agencies, including the WHO and UNAIDS, issued a statement when this
research was first presented at a meeting in Brazil in July 2005:
http://www.who.int/mediacentre/news/releases/2005/pr32/en/
UNAIDS (http://www.unaids.org) has information about the state of the
HIV/AIDS epidemic and prevention strategies. It produces an annual
report and has documents on a wide range of topics. The Q&A
documents are particularly useful:
http://www.unaids.org/EN/resources/questions_answers.asp#II
Many organizations provide information on AIDS prevention—for
example, the Terrence Higgins Trust:
http://www.tht.org.uk
AEGIS is the world’s largest searchable database on HIV and AIDS:
http://www.aegis.com
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